Deranged growth factors as a prognosticator of cardiovascular risks in patients with uterine fibroids

S. Bokhari, S. Ahmad, U. Rafi, MA. Iqbal, MA Khan, N. Roohi

Article ID: 3904
Vol 36, Issue 1, 2022
DOI: https://doi.org/10.23812/21-437-A
Received: 11 March 2022; Accepted: 11 March 2022; Available online: 11 March 2022; Issue release: 11 March 2022

Abstract

Background: Angiogenesis is a crucial factor for the pathogenesis and growth of fibroids. Among various growth factors, transforming growth factor (TGFβ1) and vascular endothelial growth factor (VEGF) are up-regulated in leiomyomas and have angiogenic as well as pro-atherogenic properties. Subsequently, their elevated values may be involved in developing cardiovascular disorders.Objective: The current study was planned to evaluate the role of growth factors in females with uterine fibroids and investigate the future risks of developing cardiovascular disorders (CVD) in these patients.Method: Eighty-two subjects of uterine fibroids and eighty-two healthy controls were selected from tertiary care hospitals. Enzyme-linked immunosorbent assay (ELISA) was utilized to assess growth factors. Results: The levels of TGFβ1 and VEGF were significantly higher (P < 0.001) in patients with uterine fibroids compared to healthy females without uterine fibroids.Conclusion: High level of circulating growth factors in patients with uterine fibroids prognosticate (CVD) events in these patients.


Keywords

VEGF;TGFβ1;Uterine Fibroids;CVD


References

Supporting Agencies



Copyright (c) 2022 S. Bokhari, S. Ahmad, U. Rafi, MA. Iqbal, MA Khan, N. Roohi




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).